Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 12/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PRKCB | P05771 | 1/20 | 0.38 |
| ▸ | PRKCA | P17252 | 1/20 | 0.38 |
| ▸ | PRKCH | P24723 | 1/20 | 0.38 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12198652 | 0.74 | HRH3 (0.56) | HRH3IRAK4MEN1ALDH1A1HPGD | |
| SCHEMBL29445680 | 0.74 | HRH3 (0.56) | HRH3IRAK4MEN1ALDH1A1HPGD | |
| SCHEMBL16019054 | 0.70 | HRH3 (0.50) | HRH3IRAK4MEN1ALDH1A1HPGD | |
| SCHEMBL5943488 | 0.69 | NCF1 (0.52) | HRH3IRAK4MEN1ALDH1A1HPGD | |
| SCHEMBL11734758 | 0.69 | CASP6 (0.62) | SYKROCK2ROCK1ALDH1A1KMT2A | |
| SCHEMBL16019055 | 0.68 | TLR8 (0.51) | HRH3IRAK4MEN1ALDH1A1HPGD | |
| SCHEMBL30125146 | 0.68 | APP (0.67) | SYKROCK2ROCK1MEN1KMT2A | |
| SCHEMBL8354796 | 0.65 | NCF1 (0.50) | HRH3HPGDHSD17B10 | |
| SCHEMBL6327167 | 0.65 | PRMT5 (0.51) | MEN1ALDH1A1KMT2A | |
| SCHEMBL7628718 | 0.64 | POLB (0.70) | HRH3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230054976-A1 | METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES | UNIVERSITY OF FLORIDA BOARD OF TRUSTEES | 2023-02-23 | — | — | US | disclosed |
| WO-2021127367-A9 | METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230054976-A1 | METHODS FOR INHIBITION OF ALPHA-SYNUCLEIN mRNA USING SMALL MOLECULES | SNCA, EIF2AK2, LRRK2 | SYK 4568/4885HRH3 2941/4885ROCK2 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.